RxDoctor Payments DataLook up a doctor →

Marcy Flecker, MD

Family Medicine · Smithfield, PANPI 1508875774

Payments from drug & device makers

$6,923,378in general payments, 2019–2025

Across 2,415 payments — averaging $2866.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1.8M
  • Genentech, Inc.$1M
  • Novartis$799K
  • Pfizer$647K
  • Cue Health Inc.$518K
  • Eli Lilly$468K
  • plus $1.7M from 54 others
$5,976in research payments, 2019–2025

Across 2 payments — averaging $2987.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$6K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)649$1,795,010
Genentech, Inc.124$1,028,915
Novartis18$799,449
Pfizer151$646,657
Cue Health Inc.2$518,260
Eli Lilly19$468,161
GSK240$363,440
AstraZeneca101$362,112
Kowa Research Institute, Inc.37$192,299
Orasure Technologies Inc.16$126,750
Hikma Pharmaceuticals USA11$107,196
Quidel Corporation3$102,000
H. Lundbeck A S10$72,269
Abbott10$70,785
Adaptive Biotechnologies Corporation1$59,364
Ardelyx, Inc.40$51,437
Chiesi USA, Inc.12$46,346
Esperion Therapeutics, Inc.83$43,745
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)6$23,270
Novo Nordisk AS9$17,513
Eli Lilly Export S.A. Puerto Rico Branch1$8,892
Sanofi US Services Inc.3$4,460
Novo Nordisk201$2,794
Biocryst Pharmaceuticals, Inc.1$1,865
Lilly USA, LLC131$1,812
Boehringer Ingelheim119$1,429
Johnson & Johnson59$794
Amarin Pharma, Inc.40$697
Amgen30$495
Bayer33$492
Takeda Pharmaceuticals U.S.A., Inc.20$312
Averitas Pharma Inc.14$292
Merz North America, Inc.7$281
Merck24$274
Ironwood Pharmaceuticals, Inc15$236
Cequr Corporation3$212
Astellas Pharma US Inc10$198
Azurity Pharmaceuticals, Inc.11$189
Scilex Pharmaceuticals Inc.1$186
Exact Sciences9$185
Medtronic(2 entities)9$176
E.r. Squibb & Sons, L.L.C.9$159
Biohaven Pharmaceuticals, Inc.9$151
Dexcom, Inc.11$149
Eisai Inc.9$129
Sunovion Pharmaceuticals Inc.12$126
Sanofi-aventis U.S. LLC9$122
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC8$120
Biohaven Pharmaceutical Holding Company Ltd.6$111
Shield Therapeutics Inc4$109
Daiichi Sankyo Inc.4$106
Idorsia Pharmaceuticals US Inc6$100
Teva Pharmaceuticals USA, Inc.6$85
Pulmonx Corporation1$61
Ultragenyx Pharmaceutical Inc.4$56
Grifols USA, LLC3$55
Phathom Pharmaceuticals, Inc.5$54
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$50
Insulet Corporation3$48
Otsuka America Pharmaceutical, Inc.3$46

How this compares

$6,923,378 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania →

Medicare billing

Part B allowed, 2024
$294,167
Medicare patients
540
Services billed
5,230

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other family medicine in Smithfield

See the full list for Pennsylvania →

Where these figures come from

Is this you, or does something look wrong? →